The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter

New England Journal of Medicine

Volumn 335, Issue 15, 1996, Pages 1091-1098

  Katzenstein, David A ^a   Hammer, Scott M ^b   Hughes, Michael D ^c   Gundacker, Holly ^c   Jackson, J Brooks ^d   Fiscus, Susan ^e   Rasheed, Suraiya ^f   Elbeik, Tarek ^g   Reichman, Richard ^h   Japour, Anthony ^b   Merigan, Thomas C ^a   Hirsch, Martin S ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; NUCLEOSIDE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCYTIUM; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0005150171     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199610103351502     Document Type: Article

References (27)

1. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
2. Sande MA, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy in adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993;270:2583-9.
3. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
4. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
5. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
6. Semple M, Loveday C, Weller I, Tedder R. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol 1991;35:38-45.
7. Holodniy M, Katzenstein DA, Israelski DM, Merigan TC. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest 1991;88:1755-9.
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
9. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
10. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
11. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
12. Knot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
13. Kozal MJ, Shafer RW, Winters MA, et al. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr 1994;7:832-8.
14. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
15. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994;170:553-62.
16. Armitage P. Statistical methods in medical research. Oxford, England: Blackwell Scientific, 1971.
17. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
18. Clayton D, Hills M. Statistical models in epidemiology. Oxford, England: Oxford University Press, 1993.
19. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
20. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
21. Schooley RT, Ramirez-Ronda C, Lange JMA, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996;173:1354-66.
22. Tersmette M, Lange JMA, de Goede REY, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989;1:983-5.
23. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-60.
24. Richman DD, Bozzette SA. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
25. Boucher CAB, Lange JMA, Miedema FF, et al. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992;6: 1259-64.
26. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
27. Gulick R, Mellors J, Haviir D, Eron J. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine (ZDV) and lamivudine (3TC). Presented at the Third National Retrovirology and Other Opportunistic Infections Conference, Washington, D.C., January 28-February 1, 1996.